Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis bekräftigt Engagement zur Eliminierung von Malaria und investiert USD 100 Millionen in die Erforschung und Entwicklung der nächsten Generation von Malariamedikamenten

Das Unternehmen investiert in den kommenden fünf Jahren über USD 100 Millionen, um die Erforschung und Entwicklung neuer Malariamedikamente voranzutreiben Das Engagement beinhaltet einen Ausbau...
April 17, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials

Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and...
April 17, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis renouvelle son engagement afin d'éliminer le paludisme en investissant 100 millions de dollars dans la recherche et le développement d'antipaludiques de nouvelle génération

L'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années ...
April 17, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis tender offer for AveXis commences

Basel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has...
April 16, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

Heart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care...
April 09, 2018 00:45 ET | Source: Novartis Pharma AG

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader

AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong...
April 09, 2018 00:45 ET | Source: Novartis Pharma AG

Novartis schliesst Vereinbarung zum Erwerb von AveXis Inc. für USD 8,7 Mrd ab, um Therapie der SMA zu transformieren und Position als führendes Gentherapie-und Neuroscience-Unternehmen auszubauen

Führender Produktkandidat von AveXis, AVXS-101, hat das Potenzial, erste Genersatztherapie zur einmaligen Anwendung zur Behandlung der spinalen Muskelatrophie (SMA) zu werden eine Krankheit,...
April 07, 2018 01:15 ET | Source: Novartis Pharma AG

Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation

Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World...
April 04, 2018 11:00 ET | Source: Novartis Pharma AG

Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril

Post-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to...
March 28, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO

Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,...